Li Tianbo, Liu Chencheng, Luo Yang, Gong Siming, Xiao Yingbin, Wang Xuefeng, Wang Yong
Department of Cardiovascular Surgery, The Second Affiliated Hospital (Xinqiao Hospital) of Chinese People's Liberation Army Medical University; Chongqing-China.
Anatol J Cardiol. 2019 Jan;21(1):11-17. doi: 10.14744/AnatolJCardiol.2018.40325.
To explore the clinical features and surgical treatment experience of primary cardiac valve tumor.
The present study retrospectively analyzed the clinical data of 11 patients with primary valvular tumors who underwent surgical treatment in our department from 1980 to 2016. Echocardiography of preoperative patients was indicated as a heart valve tumor. All patients underwent cardiopulmonary bypass surgery after endocardial angiography and positron emission tomography-computed tomography diagnosis, including four tumor resections-valvuloplasty and seven tumor resections-heart valve replacement. Pathological analysis was performed on all tumors. Postoperative cardiac ultrasound was followed up. Pathological analysis was performed on all tumors. All patients underwent postoperative ultrasound follow-up examination.
Primary valvular tumors are rare, accounting for only 0.034% (11/32.728) of extracorporeal circulation surgery in our center. It accounts for 2.8% (11/399) of primary cardiac tumors in the same period. Pathological study indicated that there were 10 cases of benign tumor and 1 case of low-grade sarcoma. After 0.6-16 years of follow-up, the operation effect was satisfactory.
Most of these tumors are papillary fibroelastoma located on the mitral valve, and surgical operation is the best strategy for cardiac primary valve tumors.
探讨原发性心脏瓣膜肿瘤的临床特征及外科治疗经验。
本研究回顾性分析了1980年至2016年在我科接受手术治疗的11例原发性瓣膜肿瘤患者的临床资料。术前患者经超声心动图检查提示为心脏瓣膜肿瘤。所有患者在经心内膜血管造影及正电子发射断层扫描-计算机断层扫描诊断后均接受了体外循环手术,其中4例行肿瘤切除-瓣膜成形术,7例行肿瘤切除-心脏瓣膜置换术。对所有肿瘤进行了病理分析。术后进行心脏超声随访。对所有肿瘤进行了病理分析。所有患者均接受了术后超声随访检查。
原发性瓣膜肿瘤较为罕见,在本中心体外循环手术中仅占0.034%(11/32728)。在同期原发性心脏肿瘤中占2.8%(11/399)。病理研究表明,良性肿瘤10例,低度肉瘤1例。经过0.6至16年的随访,手术效果满意。
这些肿瘤大多为位于二尖瓣的乳头状纤维弹性瘤,手术治疗是心脏原发性瓣膜肿瘤的最佳策略。